The Supreme Court declined to hear an important patent eligibility case on October 2nd, denying certiorari in CareDx v. Natera. This leaves in place a Federal Circuit ruling that invalidated CareDx's patents on its method for detecting organ transplant rejection.
The lower courts ruled the patents invalid under the judicial exception to patent eligibility for natural phenomena. The Supreme Court's denial means this important legal issue remains unsettled.
The medical diagnostics industry is disappointed by the outcome, as without reliable patent protection, investors may turn away from funding this research and scientists may avoid commercializing it. As a result, patients may never benefit from potentially life-saving tests.
[
add
]
[
|
|
...
]